HC Wainwright Estimates Evommune FY2027 Earnings

Evommune, Inc. (NYSE:EVMN) – Research analysts at HC Wainwright issued their FY2027 earnings per share estimates for shares of Evommune in a report issued on Wednesday, March 18th. HC Wainwright analyst M. Kapoor forecasts that the company will post earnings per share of ($3.30) for the year. HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock.

Evommune (NYSE:EVMN) last posted its quarterly earnings results on Thursday, March 5th. The company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.61).

Other research analysts also recently issued reports about the stock. Evercore reissued an “outperform” rating and set a $55.00 target price on shares of Evommune in a research report on Tuesday, February 10th. Wall Street Zen upgraded Evommune from a “sell” rating to a “hold” rating in a research note on Sunday, December 14th. Cantor Fitzgerald initiated coverage on Evommune in a report on Monday, December 1st. They set an “overweight” rating for the company. Oppenheimer assumed coverage on Evommune in a research report on Thursday, January 22nd. They issued an “outperform” rating and a $42.00 target price for the company. Finally, Raymond James Financial assumed coverage on Evommune in a research report on Wednesday, January 7th. They set a “strong-buy” rating and a $40.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $47.17.

Evommune Trading Down 3.2%

Shares of EVMN stock opened at $23.32 on Thursday. The company has a market capitalization of $839.81 million and a price-to-earnings ratio of -2.89. Evommune has a 52 week low of $13.89 and a 52 week high of $33.20. The stock has a 50-day moving average of $23.26.

Institutional Trading of Evommune

A number of institutional investors have recently modified their holdings of the business. EQT Fund Management S.a r.l. bought a new position in Evommune in the 4th quarter worth approximately $84,395,000. RA Capital Management L.P. bought a new stake in Evommune during the 4th quarter valued at $59,214,000. Pivotal bioVenture Partners Investment Advisor LLC bought a new stake in Evommune during the 4th quarter valued at $32,989,000. Nan Fung Group Holdings Ltd purchased a new stake in shares of Evommune during the fourth quarter worth $24,670,000. Finally, JPMorgan Chase & Co. bought a new position in shares of Evommune in the fourth quarter worth $22,408,000.

About Evommune

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.